EU/3/19/2179

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2179 was granted by the European Commission to Dipharma B.V., The Netherlands, for sodium benzoate, sodium phenylacetate for the treatment of hyperargininaemia.

Key facts

Active substance
  • Sodium benzoate
  • Sodium phenylacetate
Disease / condition
Treatment of hyperargininaemia
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2179

Sponsor's contact details

Dipharma B.V.
Prins Bernhardplein 200
1097 JB Amsterdam
The Netherlands
Tel. +41 9160 11700
E-mail: info@dipharma-group.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
Average
1 rating